Search - tctmd.com

Displaying 1 - 20 of 28

Sort: Relevancy | Date

High Risk of Major Bleeding Observed in Danish A-fib Population on Triple, Dual Antithrombotic Therapy

News Daily News

High Risk of Major Bleeding Observed in Danish A-fib Population on Triple, Dual Antithrombotic Therapy

Yael L. Maxwell

December 13, 2018

Frailty Linked to Higher Bleeding Risk Among Acute MI Patients Undergoing PCI

News Daily News

Frailty Linked to Higher Bleeding Risk Among Acute MI Patients Undergoing PCI

November 19, 2018

Plaque Characteristics on OCT Offer Clues About Atherosclerotic Causes of MINOCA

News Daily News

Plaque Characteristics on OCT Offer Clues About Atherosclerotic Causes of MINOCA

October 23, 2018

SURTAVI Stroke Analysis Published, Confirms Less Early Stroke With TAVR

News Daily News

SURTAVI Stroke Analysis Published, Confirms Less Early Stroke With TAVR

October 22, 2018

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

News Daily News

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

October 12, 2018

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

News Daily News

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

October 03, 2018

ADAPT-DES: High On-Aspirin Platelet Reactivity Not Related to PCI Outcomes

News Daily News

ADAPT-DES: High On-Aspirin Platelet Reactivity Not Related to PCI Outcomes

August 17, 2018

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

News Daily News

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

Michael O'Riordan

July 31, 2018

Is Weight-Based Dosing of Aspirin Needed for Effective Primary Prevention?

News Daily News

Is Weight-Based Dosing of Aspirin Needed for Effective Primary Prevention?

July 20, 2018

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

New Review Probes Possibility of CVD Prevention Without Aspirin

News Daily News

New Review Probes Possibility of CVD Prevention Without Aspirin

Michael O'Riordan

July 04, 2018

Leaflet Thrombosis After TAVR Not Linked With Stroke, TIA, or Mortality Risk

News Daily News

Leaflet Thrombosis After TAVR Not Linked With Stroke, TIA, or Mortality Risk

Michael O'Riordan

June 20, 2018

Platelet Reactivity Linked With Ischemic Stroke Risk Post-DES Implantation: ADAPT-DES Substudy

News Daily News

Platelet Reactivity Linked With Ischemic Stroke Risk Post-DES Implantation: ADAPT-DES Substudy

Yael L. Maxwell

June 08, 2018

Oral Anticoagulation Boosts Poststroke Outcomes in Patients With A-fib

News Daily News

Oral Anticoagulation Boosts Poststroke Outcomes in Patients With A-fib

May 18, 2018

PREDICT-1° CVD Risk Calculator, Based on Present-Day Patients, Beats ACC/AHA ‘Pooled Cohort’ Equations

News Daily News

PREDICT-1° CVD Risk Calculator, Based on Present-Day Patients, Beats ACC/AHA ‘Pooled Cohort’ Equations

Michael O'Riordan

May 10, 2018

Recent Stroke Heightens Risk of Perioperative Events After AVR

News Daily News

Recent Stroke Heightens Risk of Perioperative Events After AVR

April 25, 2018

Less Bleeding, Similar Outcomes With Dual vs Triple Therapy After PCI in Patients With A-fib

News Daily News

Less Bleeding, Similar Outcomes With Dual vs Triple Therapy After PCI in Patients With A-fib

April 24, 2018

Hybrid Coronary Revascularization at 5 Years: Similar Outcomes to CABG

News Daily News

Hybrid Coronary Revascularization at 5 Years: Similar Outcomes to CABG

Yael L. Maxwell

April 23, 2018

Abciximab in ‘Short Supply’ Worldwide

News Daily News

Abciximab in ‘Short Supply’ Worldwide

April 13, 2018

Device Thrombus After LAA Closure Strongly Linked to Stroke in Real-World Registry

News Daily News

Device Thrombus After LAA Closure Strongly Linked to Stroke in Real-World Registry

April 03, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.